HemOnc Today New York
HemOnc Today New York
April 24, 2019
4 min watch
Save

VIDEO: Novel combinations can capitalize on immunogenicity of head and neck cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW YORK — Nabil F. Saba, MD, FACP, professor of hematology/medical oncology and otolaryngology and director of the head and neck oncology program at Winship Cancer Institute at Emory University, spoke at HemOnc Today New York about combination approaches for head and neck squamous cell carcinoma in the immunotherapy era.

“Head and neck cancer ... is very immunogenic,” Saba told HemOnc Today. “The amount of infiltrative immune cells in head and neck tumors surpasses those of many other tumors, and ... data show reversal of immune suppression makes a big difference in the effectiveness of immunotherapy in this disease.”

Saba discussed the potential role of immunotherapy as part of combination therapy with radiation, chemotherapy or targeted agents.

 

Disclosure: Saba reports consultant roles with Aduro Biotech, Bristol-Myers Squibb, Celldex, Eli Lilly, Kura, Merck, Pfizer and Vaccinex, as well as funding from Bristol-Myers Squibb, Exelixis, NIH and Novartis.